Top Reasons to Subscribe Akums Drugs and Pharmaceuticals Limited IPO
About Akums Drugs and Pharmaceuticals? Ltd
Akums Drugs and Pharmaceuticals Limited, founded in 2004, is a significant pharmaceutical contract development and manufacturing organization (CDMO) that offers a diverse range of pharmaceutical goods and services in India and throughout the world.?
The firm provides comprehensive solutions that include product development, manufacturing, formulation research and development (R&D), regulatory dossier preparation and submission, and a variety of testing services. Additionally, Akums manufactures and sells branded pharmaceuticals and active pharmaceutical ingredients (APIs).
As a CDMO, Akums manufactures a wide variety of dosage forms, including tablets, capsules, liquid medications, vials, ampoules, blow-filled closures, topical treatments, eye drops, dry powder injections, and gummy bears, among others. The firm has a portfolio of 4,025 marketed formulations spanning more than 60 dosage formats. In fiscal year 2023, Akums produced formulations for 26 of India's top 30 pharmaceutical businesses by sales.
The firm runs ten manufacturing units for its CDMO business, with a total annual production capacity of 49.21 billion units as of September 30, 2023. Plans are ongoing to increase this capacity with the installation of two more manufacturing units, which will be operational in fiscal year 2025.?
Several Akums facilities have been accredited by worldwide regulatory authorities, including the European Good Manufacturing Practice (EU-GMP), World Health Organization Good Manufacturing Practice (WHO-GMP), and the United States National Sanitation Foundation (US NSF).
As of September 30, 2023, Akums Drugs & Pharmaceuticals employed 16,463 people, including 7,211 full-time employees and 9,252 contract workers.
Key Factors
Akums offers complete solutions, including product development, manufacturing, R&D, regulatory dossier preparation, and testing services. This complete service offering appeals to a wide spectrum of clients and increases customer loyalty.
The firm produces a wide variety of dosage forms, such as tablets, capsules, liquid medications, vials, ampoules, topical applications, and more. This versatility enables Akums to meet a wide range of market demands and client preferences.
In FY 2023, Akums produced formulations for 26 of India's top 30 pharmaceutical businesses by sales. This substantial client base demonstrates the company's repute and dependability in the pharmaceutical business.
Akums runs ten manufacturing facilities, with a total yearly production capacity of 49.21 billion units. This huge capacity enables the organization to satisfy large-scale demand effectively.
The company's facilities have been accredited by key worldwide regulatory authorities, including the EU-GMP, WHO-GMP, and the US NSF. These certifications boost the company's reputation and allow it to compete in global marketplaces.
领英推荐
Akums employs 16,463 people, including a significant number of full-time and contract employees, and has a trained workforce capable of handling complicated industrial processes while keeping high quality standards.
Akums aims to increase manufacturing capacity by commissioning two more units in FY2025. This development is projected to increase the company's production capacity and income potential.
Key Details
IPO Date: 30 July 2024 to 01 August 2024
Face Value: ?2 per share
Price Band: ?646 to ?679 per share
Lot Size: 22 Shares?
Total Issue Size: ?1,856.74 Cr
Objectives Of The IPO
Conclusion
Akums Drugs and Pharmaceuticals Limited, established in 2004, is a prominent CDMO providing a comprehensive range of pharmaceutical products and services in India and internationally.?
The company excels in product development, manufacturing, R&D, regulatory compliance, and testing, making it a preferred partner for major pharmaceutical firms.?
With a robust portfolio of 4,025 formulations and a significant production capacity, Akums is poised for growth, further supported by its global accreditations and expansion plans.?
The company's IPO, scheduled from July 30 to August 1, 2024, offers an attractive investment opportunity with a price band of ?646 to ?679 per share.